We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hey Coldspy! Yes all well. Hope your stocks are doing well after our last one!
You in here?
SPIKE?? :)))
My old friend, how are you? Long time no see
I'm in LOGP now, come visit us soon...
Colin you can buy as much as you want and it’s NT to sell
You really are embarrassing yourself trying to mislead people on here
I suggest you do some research on the company before posting
Ffs read the RNS! Production is 12 months from filing in Russia! It’s in black and white in the last RNS!
Colin means that he has only just seen the Ovoca Bio website page which hasn't changed since December 2018.
Its just his attempt at pump and dump.
What website? Please can you direct me to the infomration you've seen?
It spiked last Thursday then slid back down to where we are.
Nice to see decent buys again,NT on any reasonable size back to 20 p
So read the info from OVB recently placed on their web site. Clearly states third party to produce and clarifies Junipers evolvement through the trail period
From OVB
The drug is produced by contract manufacturing organisations (CMOs). IVIX does not have and does not intend to develop its own manufacturing facilities until significant revenues from sales are achieved. For drug manufacturing, IVIX has chosen CMOs with strong track records of quality assurance and regulatory compliance. In Russia, the drug is manufactured by Nativa LLC, a CMO which has numerous peptide drugs in its portfolio that have been successfully produced for the Russian market.
Juniper Pharma Services, located in Nottingham, UK, will fulfil the second part of the drug manufacturing cycle for IVIX, namely production of the final drug product. Juniper Pharma Services have strong experience in the manufacturing of ready dosage forms for clinical trials, under a Medicines and Healthcare Products Regulatory Agency (MHRA) license.
The glass vials and nasal spray pump for the drug product are manufactured by SGD (France) and Aptar (Germany) respectively, both established firms in their respective areas with strong track records of product quality assurance.
Juniper can find other sources to produce such a large production scale of Libicore. And OVB have stated that they want to expand into production themselves as well as R & D. But their product is tapping into a £BN market and have attracted bigger players whom be interested in buying Libicore and producing themselves.The key here was always getting approval and whilst the Licence is awaiting, We will be expecting third parties come forward with their proposals.
That statement is from the RNS in July 2018 and was probably outlining production just for the clinic trials. I could be wrong though.
"Juniper Pharma Services, located in Nottingham, UK, will fulfil the second part of the drug manufacturing cycle for IVIX, namely production of the final drug product. Juniper Pharma Services have strong experience in the manufacturing of ready dosage forms for clinical trials, under a Medicines and Healthcare Products Regulatory Agency (MHRA) license. "
Why are you expecting such news when they've already announce that Juniper will produce the final product. Bachem will produce the active ingredient.
This is all in the public domain.
Expecting RNS from OVB confirming JV interested party to produce and distribute Libicore.
Be massive re-rate if Bachem AG confirms they are in discussions and going to either buy the Patent rights for 20 Years or JV
Either way its a win win for OVB.
Bachem AG - a huge Swiss pharma attending IMAP 2019 at the end of August will be mentioning Libicore.
MM's caught out again, dropped on a few sells required for liquidity .
Think the party might be over for today.
If this rise is sustained just watch investors pile in again!
It's on the move again.